Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with established causes of infertility and indications for the use of ART methods, according to the Order of the Ministry of Health of the Russian Federation On the use of assisted reproductive technologies, contraindications and limitations to their use No. 107 n dated August 30, 2012.~* Infertility due to female and/or male factor.~* Presence of ovaries accessible for aspiration of follicles.~* Anatomical and functional capability of uterus to bear pregnancy.~Exclusion Criteria:~* Women with established contraindications to the use of ART methods, according to the Order of the Ministry of Health of the Russian Federation On the use of assisted reproductive technologies, contraindications and limitations to their use No. 107 n dated August 30, 2012.~* Presence of pregnancy~* Hypersensitivity to follitropin alfa or excipients.~* Ovarian cysts (not associated with polycystic ovarian syndrome), uterine hemorrhage of unclear etiology~* Premature ovarian failure~* Presence of clinically significant systemic disease~* Presence of chronic cardiovascular, hepatic, renal or pulmonary disease~* Neoplasia~* Narcomania, alcoholism

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 43 Years
- Healthy Volunteers: f

Study Arms:
- Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH (Type: None): The ovarian stimulation (OS) protocols included monotherapy protocols with using follitropin alpha biosimilar only and antagonists/agonists of of gonadotropin-releasing hormone (GnRH): ganirelix, cetrorelix, triptorelin, buserelin.
- Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH (Type: None): The OS protocols included: mixed protocols (recombinant with addition of urinary-derived gonadotropins) and antagonists/agonists of GnRH (ganirelix, cetrorelix, triptorelin, buserelin), where follitropin alpha biosimilar used for at least 5 days during OS.
- Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH (Type: None): The OS protocols included: monotherapy protocols with using only follitropin alpha biosimilar and antagonists of GnRH.
- Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH (Type: None): The OS protocol included: monotherapy protocols with using only follitropin alpha biosimilar and agonists of GnRH.
- The overall protocols (Type: None): The OS protocols included: (1) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH, (2) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH

Based on this trial design, predict the completion outcome and termination type (if applicable).